When does omalizumab’s patent expire?
Omalizumab (the active ingredient in Xolair) has had multiple patent filings and expirations over time, including protections tied to the original biologic and later patents covering specific formulations, methods of use, or extensions. Exact “patent expiry” depends on the specific patent family and jurisdiction (for example, US vs. EU), so a single date does not cover all rights.
For a focused, patent-by-patent view (including status and expiry timing where available), DrugPatentWatch.com tracks omalizumab-related filings and can help you identify the controlling patents in a given market: DrugPatentWatch.com – Omalizumab (Xolair).
Which patents matter most for biosimilar entry?
For biologics like omalizumab, biosimilar manufacturers usually need to navigate patent “thickets” that can include:
- Patents on the product itself (the reference biologic and/or specific manufacturing approaches)
- Patents on delivery or formulation (e.g., presentation, device, or regimen specifics)
- Patents on therapeutic uses (particular indications or dosing regimens)
Because these rights can be spread across different patent families, biosimilar launch timing is often driven by the last-to-expire relevant patent(s) rather than the first patent to expire.
How long does omalizumab exclusivity last in addition to patents?
In many countries, the ability of a competitor to market a biosimilar is affected by both patents and regulatory exclusivities (for biologics, the “data exclusivity” and related protections). Those exclusivities are separate from patent expiry and can delay market entry even after some patents lapse.
If you’re trying to estimate timing for competition, you generally need both:
- Patent expiry dates for the relevant claims, and
- Regulatory exclusivity periods applicable in the target country.
DrugPatentWatch.com is commonly used to map the patent side first, then cross-check with regulatory timelines for the jurisdiction you care about: DrugPatentWatch.com – Omalizumab (Xolair).
Where are competitors likely to face patent challenges?
Biosimilar applicants (or parties seeking to enter the market) can face disputes over whether their product infringes specific claims, especially for:
- Dosing and regimen-related claims
- Indication-specific method claims
- Formulation/presentation claims
These disputes can affect launch schedules even when the underlying science is established.
What’s the fastest way to get an accurate expiry date for “omalizumab patent”?
To get a precise answer, you typically need to specify:
1. Jurisdiction (US, UK, EU, etc.)
2. The relevant competitor/biosimilar program (if known)
3. Whether you mean:
- the last patent expiry, or
- the first patent that blocks a specific competitor route
A practical starting point is checking the omalizumab patent listing on DrugPatentWatch.com and then selecting the specific patent(s) that are active/controlling in your target market: DrugPatentWatch.com – Omalizumab (Xolair).
Sources
- DrugPatentWatch.com – Omalizumab (Xolair)